A magnetic resonance imaging white matter hyperintensities region recognizing method and system are disclosed herein. The white matter hyperintensities region recognizing method includes receiving and storing a FLAIR MRI image, a spin-lattice relaxation time weighted MRI image, and a diffusion weighted MRI image. Registration and fusion are preformed, and a white matter mask is determined. An intersection image of the FLAIR MRI image and the white matter mask is taken, a first region is determined after normalizing the intersection image, a cerebral infarct region is removed from the first image through the diffusion weighted MRI image, and then a determination is made as to whether to remove a remaining region in order to form a white matter hyperintensities region in the FLAIR MRI image.

National Central University

Chang; Huan-Cheng

Magnetic resonance imaging white matter hyperintensities region recognizing method and system

Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases. ##STR1##

Kinacia Pty. Ltd.

Therapeutic morpholino-substituted compounds

Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases. ##STR00001##

AstraZeneca AB

Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

The peak potential values of each cardioelectric wave components detected from the body surface are uniquely presented as a few iso-potential and isochronous contour maps by the electrocardiac peak mapping (EPM) method and apparatus described. The change in the size and the contour of the relevant EPM maps provides a simple, non-invasive, yet sensitive means for clinical diagnosis of at least the following heart diseases:1) the locations and sizes of myocardial infarction (hereafter, MI),2) primary and second cardiomyopathies,3) locations and sizes of "non-Q-wave MI", which can not be diagnosed by conventional electrocardiography, and4) various intracardiac conduction blocks and Wolff-Parkinson-White syndrome,5) various repolarization abnormalities and their quantitative analysis.The EPM apparatus comprises an elastic Waistcoat with embodied special electrodes, signal preprocessors, a multiplexer, a main differential amplifier, and a general purpose computer with appropriate software. The EPM analysis includes the identification of the peak potential and peak time displacement, the contruction of the isopotential and isochronous maps and the diagnosis of heart diseases. The diagnosis is achieved by comparison of the statistically obtained normal values to that of a patient. The complete EPM process can be carried out within ten minutes.

white/infarction

Magnetic resonance imaging white matter hyperintensities region recognizing method and system

Therapeutic morpholino-substituted compounds

Therapeutic morpholino-substituted compounds

Therapeutic morpholino-substituted compounds

Method and apparatus for recording and analyzing body surface electrocardiographic peak maps

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi